Combination of Glofitamab with Pirtobrutinib in BTK Inhibitor (BTKi)-Naive or Btki-Intolerant Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

Madhav Seshadri(University of California, San Francisco), Charalambos Andreadis(University of California, San Francisco), Lauren Nguyen(University of California, San Francisco), William Pearse(University of California San Diego), Weiyun Z. Ai(City College of San Francisco), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Naseem Esteghamat(University of California System), Chiung‐Yu Huang, Patricia A. Young(University of Maryland, Baltimore County), Monica Mead(UCLA Medical Center), Michael A. Spinner(Stanford Medicine)
Blood
November 5, 2024
10.1182/blood-2024-209493
Cited by 1

Related Papers

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487